This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esler, W. P. Articles by Sweet, L. J. Search for Related Content PubMed PubMed Citation Articles by Esler, W. P. Articles by Sweet, L. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Weight Control

Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss

Bayer Research Center, Bayer Healthcare, West Haven, Connecticut 06516

Address all correspondence and requests for reprints to: William Esler, Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, MS 8220-3336, Eastern Point Road, Groton, Connecticut 06340. E-mail: william.esler{at}pfizer.com; or Joachim Rudolph, Genentech Inc., Medicinal Chemistry, 1 DNA Way, South San Francisco, California 94080. E-mail: rudolph.joachim{at}gene.com.

Ghrelin, through action on its receptor, GH secretagogue receptor type 1a (GHS-R1a), exerts a variety of metabolic functions including stimulation of appetite and weight gain and suppression of insulin secretion. In the present study, we examined the effects of novel small-molecule GHS-R1a antagonists on insulin secretion, glucose tolerance, and weight loss. Ghrelin dose-dependently suppressed insulin secretion from dispersed rat islets. This effect was fully blocked by a GHS-R1a antagonist. Consistent with this observation, a single oral dose of a GHS-R1a antagonist improved glucose homeostasis in an ip glucose tolerance test in rat. Improvement in glucose tolerance was attributed to increased insulin secretion. Daily oral administration of a GHS-R1a antagonist to diet-induced obese mice led to reduced food intake and weight loss (up to 15%) due to selective loss of fat mass. Pair-feeding experiments indicated that weight loss was largely a consequence of reduced food intake. The impact of a GHS-R1a antagonist on gastric emptying was also examined. Although the GHS-R1a antagonist modestly delayed gastric emptying at the highest dose tested (10 mg/kg), delayed gastric emptying does not appear to be a requirement for weight loss because lower doses produced weight loss without an effect on gastric emptying. Consistent with the hypothesis that ghrelin regulates feeding centrally, the anorexigenic effects of potent GHS-R1a antagonists in mice appeared to correspond with their brain exposure. These observations demonstrate that GHS-R1a antagonists have the potential to improve the diabetic condition by promoting glucose-dependent insulin secretion and promoting weight loss.

This article has been cited by other articles:

				P. S. Petersen, D. P. D. Woldbye, A. N. Madsen, K. L. Egerod, C. Jin, M. Lang, M. Rasmussen, A. G. Beck-Sickinger, and B. Holst In Vivo Characterization of High Basal Signaling from the Ghrelin Receptor Endocrinology, November 1, 2009; 150(11): 4920 - 4930. [Abstract] [Full Text] [PDF]

				T. H. Moran and M. J. Dailey Gut Peptides: Targets for Antiobesity Drug Development? Endocrinology, June 1, 2009; 150(6): 2526 - 2530. [Abstract] [Full Text] [PDF]

				S.-C. Lu, J. Xu, N. Chinookoswong, S. Liu, S. Steavenson, C. Gegg, D. Brankow, R. Lindberg, M. Veniant, and W. Gu An Acyl-Ghrelin-Specific Neutralizing Antibody Inhibits the Acute Ghrelin-Mediated Orexigenic Effects in Mice Mol. Pharmacol., April 1, 2009; 75(4): 901 - 907. [Abstract] [Full Text] [PDF]

				A. V. Mayorov, N. Amara, J. Y. Chang, J. A. Moss, M. S. Hixon, D. I. Ruiz, M. M. Meijler, E. P. Zorrilla, and K. D. Janda Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice PNAS, November 11, 2008; 105(45): 17487 - 17492. [Abstract] [Full Text] [PDF]

				F. Lanfranco, L. Bonelli, M. Baldi, E. Me, F. Broglio, and E. Ghigo Acylated Ghrelin Inhibits Spontaneous Luteinizing Hormone Pulsatility and Responsiveness to Naloxone But Not That to Gonadotropin-Releasing Hormone in Young Men: Evidence for a Central Inhibitory Action of Ghrelin on the Gonadal Axis J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3633 - 3639. [Abstract] [Full Text] [PDF]

				R. S. Ahima Antagonism of Ghrelin for Glycemic Control in Type 2 Diabetes Mellitus? Endocrinology, November 1, 2007; 148(11): 5173 - 5174. [Full Text] [PDF]